AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 191 min read$SNOA

Sonoma Pharmaceuticals, Inc. (SNOA): Submission of Matters to a Vote of Security Holders

Sonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On August 19, 2026, Sonoma Pharmaceuticals, Inc. (the “Company”) held an adjourned special meeting of stockholders (the “Special Meeting”), pursuant to a definitive proxy statement, filed with the Securities and Exch

Original reporting
SEC EDGAR 8-K
Published Aug 19, 2026, 9:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$SNOA
Neutral
medium confidence
Mentioned
$SNOA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SNOANeutralLow
01

Why it matters

The cancellation postpones any shareholder votes, which could affect upcoming corporate actions.

02

Market read

Governance‑related filing with limited immediate trading impact.

03

What to watch

Potential upcoming proxy materials or shareholder proposals that could be delayed.

Relevance 6/10Novelty 4/10Timing: after‑hours filing

Background

The filing is a standard SEC 8‑K disclosure of a special meeting that failed to achieve quorum and was therefore cancelled.

Company-level read

Ticker impact

$SNOANeutralMedium confidence
Context

SEC 8‑K reports that a special shareholders' meeting was cancelled due to lack of quorum.

Expected impact

Potential short‑term downside pressure as investors await clarification.

Evidence & confidence

No immediate financial transaction, but governance uncertainty can affect sentiment.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

Limited to investors holding SNOA.

Global

Low

Counterpoint

What could challenge this read

The meeting cancellation may be a procedural issue with no material effect on the company's fundamentals.

Key entities

  • company
    Sonoma Pharmaceuticals, Inc.

    Biopharmaceutical company filing the 8‑K.

Read at source← All news

Related articles

JUN 16
$SNOAMedAI 8/10

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

Sonoma Pharmaceuticals (Nasdaq:SNOA) reported fourth-quarter FY2026 results for the quarter ended March 31, 2026. Revenue rose to $5.6M (+48%) from $3.8M; gross profit was $2.2M (39%). Net loss was $0.6M, and EBITDA loss improved 66% to $0.2M. For FY2026, revenue increased to $19.5M (+$5.2M) and EBITDA loss fell 38% to $2.1M. Cash was $2.4M.

finanznachrichten.de6 min
SEP 17
$AONMedAI 9/10

Aon plc (AON): Other Events

Aon plc (AON) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 14, 2026, Aon North America, Inc., a Delaware corporation (“ANA”), Aon Global Holdings plc, a public limited company formed under the laws of England and Wales (“AGH” and, together with ANA, the “Issuers”), Aon plc, an Irish public limited com

SEC EDGAR 8-K2 min
SEP 17
$CICBMed

CION Investment Corp (CICB): Other Events

CION Investment Corp (CICB) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 17, 2026, CĪON Investment Corporation (“CION”) entered into an Amended and Restated Limited Liability Company Agreement (the “LLC Agreement”) of Senior Loan Fund Partners, LLC (the “Joint Venture”), a newly formed Delaware limited liability c

SEC EDGAR 8-K2 min